XERIS BIOPHARMA HOLDINGS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect three Class I directors to our board of directors to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: BJ Bormann

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“Elect Director: BJ Bormann”): 57,050,196 for, 21,676,213 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each nominee was elected by a plurality vote in accordance with the Company's Bylaws, as follows:”
Support: 72% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 21,758,930 for, 2,454,121 withheld.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To elect three Class I directors to our board of directors to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Garheng Kong

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“Elect Director: Garheng Kong”): 75,938,627 for, 2,787,782 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each nominee was elected by a plurality vote in accordance with the Company's Bylaws, as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 24,037,221 for, 175,830 withheld.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To elect three Class I directors to our board of directors to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: James Brady

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“Elect Director: James Brady”): 76,465,887 for, 2,260,522 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each nominee was elected by a plurality vote in accordance with the Company's Bylaws, as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 24,197,168 for, 15,883 withheld.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers.

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“3. Advisory Vote to Approve Named Executive Officer Compensation”): 72,202,176 for, 5,633,615 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three: Advisory Vote to Approve Named Executive Officer Compensation The Company's stockholders approved, on a non-binding advisory basis, to approve the compensation of the Company's Named Executive Officers as disclosed in the Company's Proxy Statement pursuant to the compensation disclo…”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 49 managers: 23,783,279 for, 413,889 against, 15,883 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 137 managers: 32,203,131 for, 2,954,238 against, 12,251 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 110,053,757 for, 744,492 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm Stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 24,198,168 for, 15,883 abstained.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.